Sweden's Modus Therapeutics Q1 net loss widens

Modus Therapeutics Holding AB

26/05/2026 07:08

Overview

Sweden biotech firm's Q1 net loss widened yr/yr

Q1 loss per share was SEK 0.03, compared to SEK 0.08 a year ago

Company raised SEK 9.5 mln post-quarter via warrant exercise to support drug development

Outlook

Modus expects proof-of-concept readout from Phase IIa CKD study by end-2026

Company says strengthened financial position supports execution through anticipated Phase IIa readout

Modus sees continued scientific validation for sevuparin in CKD with anemia

Result Drivers

CLINICAL TRIAL PROGRESS - Continued patient enrollment in Phase IIa CKD with anemia study proceeded according to plan, per company

SCIENTIFIC VALIDATION - Acceptance of sevuparin abstracts for presentation at EHA2026 and EIC 2026 reinforced scientific foundation, co said

FINANCIAL POSITION - Post-quarter warrant exercise raised SEK 9.5 mln to support ongoing development, co said

Company press release: ID:nMFN3ZprQ8

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-SEK 0.03
Q1 Net Income
-SEK 3.28 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)